Results 31 to 40 of about 411,617 (199)

Cost-effectiveness of insulin degludec versus insulin glargine U100 in adults with type 1 and type 2 diabetes mellitus in Bulgaria

BMC Endocrine Disorders, 2019
Background This analysis evaluates the cost-effectiveness of insulin degludec (degludec) versus biosimilar insulin glargine U100 (glargine U100) in patients with type 1 (T1DM) and type 2 diabetes mellitus (T2DM) in Bulgaria.
Monika Russel-Szymczyk, Vasil Valov, Alexandra Savova, Manoela Manova   +3 more
doaj   +1 more source

Comparative efficacy of GLP‐1 RA, tirzepatide and SGLT‐2 inhibitors in metabolic liver disease: A network meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Aim Metabolic liver disease, including nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis, is a major cause of chronic liver dysfunction worldwide, creating an urgent need for effective treatments. This systematic literature review (SLR) and network meta‐analysis (NMA) systematically reviews and compares the efficacy and safety ...
Andrej Belančić, Christina Antza, Anastasios Poutachidis, Smaro Palaska, Elvira Meni Maria Gkrinia, Andrea Katrin Faour, Yusuf Ziya Sener, Seher Sener, Rehena Sultana   +8 more
wiley   +1 more source

The use of long-acting insulin degludec in adult patients with type 2 diabetes mellitus in real clinical practice in Russia

Сахарный диабет, 2023
BACKGROUND: Effective glycaemic control remains the most important task in managing the risks of Diabetes type 2 complications development. In this regard, the choice of insulin preparations with minimal variability of action is of utmost importance ...
G. R. Galstyan
doaj   +1 more source

Safety outcomes of antidiabetic medications: A comprehensive review of the EU summaries of product characteristics and international clinical practice guidelines

British Journal of Clinical Pharmacology, EarlyView.
Aims Information on the safety profile of antidiabetic medications is essential for informed treatment decisions in type 2 diabetes mellitus. Although this information is available in regulatory documents of individual drugs, a comprehensive overview across all approved antidiabetics is lacking.
David Liang, Daniala L. Weir, Safana Thevasahayam, Vera H. M. Deneer, Arno Siebes, Helga Gardarsdottir   +5 more
wiley   +1 more source

Considerations for the Integration of Clinical Trials and Real‐World Data

Clinical Pharmacology &Therapeutics, EarlyView.
As clinical decision‐making increasingly moves toward individualized and context‐specific treatment recommendations, reliance on any single evidence source, randomized or observational, may be insufficient. Principled integration of randomized controlled trials and real‐world data, grounded in explicit causal frameworks, offers a path toward evidence ...
Sky Qiu, Charles E. Barr, Lauren Dang, Larry Han, Kajsa Kvist, Hana Lee, Andrew Mertens, Nerissa Nance, Lei Nie, Kara Rudolph, Xu Shi, Jens Tarp, Salina P. Waddy, Kenneth Wiley, Andy Wilson, Margot Lisa Jing Yann, Zhiwei Zhang, Tianyue Zhou, Maya Petersen, Mark van der Laan   +19 more
wiley   +1 more source

Efficacy and safety of insulin degludec in renal transplant recipients with pre-existing diabetes

Endocrine and Metabolic Science, 2021
Introduction: Glycemic control is important in renal transplant receptions with diabetes. In the early post-transplant period, recovering renal function and concomitant steroids and immunosuppressants increase the risk of dysglycemia which adversely ...
Debmalya Sanyal, Soumyabrata Roy Chaudhuri, Anirban Majumder   +2 more
doaj   +1 more source

Anti‐obesity medications and incident ocular outcomes: A systematic review and network meta‐analysis

VIEW, EarlyView.
In this systematic review and network meta‑analysis of 140 studies, anti‑obesity medications showed heterogeneous ocular safety profiles. Semaglutide was associated with higher NAION risk (observational data), whereas dual/multi‑agonists and glucagon‐like peptide‐1 receptor agonists demonstrated favourable glaucoma and overall ocular outcomes ...
Linge Jian, Keke Zhang, Wenwen He, Yan Ke, Yi Lu, Xiangjia Zhu   +5 more
wiley   +1 more source

THE USE OF ULTRA-LONG-ACTING INSULIN ANALOGUE DEGLUDEC IN TYPE 1 DIABETES MELLITUS IN CLINICAL PRACTICE: THE INFLUENCE ON QUALITY OF LIFE AND SATISFACTION WITH TREATMENT

Alʹmanah Kliničeskoj Mediciny, 2016
Background: Maintenance of stable glycemic control is an important prerequisite of effective treatment of patients with type 1 diabetes mellitus (DM).
M. F. Kalashnikova, D. R. Yazykova, N. V. Likhodey, A. V. Zilov, Yu. P. Sych, E. S. Maloletkina, V. V. Fadeev   +6 more
doaj   +1 more source

Impact of incretin analogues on lipid and lipoprotein metabolism in obesity and diabetes

British Journal of Pharmacology, EarlyView.
Abstract Incretin‐based therapies have gained momentum as a key strategy for reducing cardiovascular risk in individuals with obesity and/or type 2 diabetes (T2D). It remains unclear whether the cardiovascular benefits reflect a direct reduction in atherogenic lipoproteins—namely, low‐density lipoproteins (LDL), very low‐density lipoproteins (VLDL) and
Andrea Baragetti, Giuseppe Danilo Norata
wiley   +1 more source

Basal insulin analogues in the treatment of diabetes mellitus: What progress have we made?

Indian Journal of Endocrinology and Metabolism, 2015
Over the past few decades, continuous progress has been made in the development of insulin therapy. Basal insulins were developed around 60 years ago. However, existing basal insulins were found to have limitations. An ideal basal insulin should have the
Sanjay Kalra
doaj   +1 more source